Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation.
性状
Liquid
IC50 & Target[1][2]
Interleukin-2 receptor
体外研究(In Vitro)
Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα.Basiliximab binds only to activated lymphocytes and macrophages/monocytes. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76.[2]. Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1.[3]. Chapman TM, et